Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VIR
- Price
- 5.53
- Stock movement up
- +0.25 (4.73%)
- Company name
- Vir Biotechnology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 761.59M
- Ent value
- 850.87M
- Price/Sales
- 9.69
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 24.65%
- 1 year return
- -39.16%
- 3 year return
- -37.20%
- 5 year return
- -29.65%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VIR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.69 |
| Price to Book | 0.61 |
| EV to Sales | 10.82 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 137.72M |
| EPS (TTM) | -3.90 |
| FCF per share (TTM) | -3.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 78.62M |
| Gross profit (TTM) | 64.40M |
| Operating income (TTM) | -517.55M |
| Net income (TTM) | -533.34M |
| EPS (TTM) | -3.90 |
| EPS (1y forward) | -3.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.92% |
| Operating margin (TTM) | -658.31% |
| Profit margin (TTM) | -678.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 168.35M |
| Net receivables | 5.30M |
| Total current assets | 1.05B |
| Goodwill | 16.94M |
| Intangible assets | 19.26M |
| Property, plant and equipment | 160.76M |
| Total assets | 1.50B |
| Accounts payable | 7.30M |
| Short/Current long term debt | 112.81M |
| Total current liabilities | 117.16M |
| Total liabilities | 257.63M |
| Shareholder's equity | 1.24B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -466.64M |
| Capital expenditures (TTM) | 6.43M |
| Free cash flow (TTM) | -473.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -42.99% |
| Return on Assets | -35.60% |
| Return on Invested Capital | -42.32% |
| Cash Return on Invested Capital | -37.54% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.29 |
| Daily high | 5.55 |
| Daily low | 5.23 |
| Daily Volume | 1.22M |
| All-time high | 83.07 |
| 1y analyst estimate | 29.50 |
| Beta | 0.46 |
| EPS (TTM) | -3.90 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| VIR | S&P500 | |
| Current price drop from All-time high | -93.34% | -12.89% |
| Highest price drop | -93.75% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -62.51% | -11.07% |
| Avg time to new high | 99 days | 12 days |
| Max time to new high | 1058 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
761.59M
Marketcap category
Small-cap
Description
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Employees
587
Website
Investor relations
-
SEC filings
CEO
George A. Scangos
Country
USA
City
San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page